Acute Myocardial Infarction following Naltrexone Consumption; a Case Report
Archives of Academic Emergency Medicine,
Vol. 5 No. 1 (2017),
1 January 2017
,
Page e45
https://doi.org/10.22037/aaem.v5i1.170
Abstract
Cardiovascular effects of opioid withdrawal have long been studied. It was reported that patients with underlying ischemic heart disease and atherosclerotic vessels may be complicated by a sudden physical and emotional stress due to withdrawal syndrome. But some other believes sudden increase in catecholamine level as a sympathetic overflow might effect on heart with and without underlying ischemia. In the current study, a patient on methadone maintenance therapy (MMT) who experienced myocardial infarction (MI) after taking naltrexone was described.- Cardiovascular effects of opioid withdrawal have long been studied. It was reported that patients with underlying ischemic heart disease and atherosclerotic vessels may be complicated by a sudden physical and emotional stress due to withdrawal syndrome. B
How to Cite
References
Schwartz BG, Mayeda GS, Burstein S, Economides C, Kloner RA. When and why do heart attacks occur? Cardiovascular triggers and their potential role. Hospital Practice. 2010;38(3):144-52.
Ramadan R, Sheps D, Esteves F, Zafari AM, Bremner JD, Vaccarino V, et al. Myocardial ischemia during mental stress: role of coronary artery disease burden and vasomotion. Journal of the American Heart Association. 2013;2(5):e000321.
Masoomi M, Zare J, Nasri H, Mirzazadeh A, Sheikhvatan M. Abrupt opium discontinuation has no significant triggering effect on acute myocardial infarction. Journal of Cardiovascular Medicine. 2011;12(4):234-8.
Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase β inhibition during reperfusion in intact rat hearts. Circulation research. 2004;94(7):960-6.
Marmor M, Penn A, Widmer K, Levin RI, Maslansky R. Coronary artery disease and opioid use. The American journal of cardiology. 2004;93(10):1295-7.
Gross ER, Hsu AK, Gross GJ. Acute methadone treatment reduces myocardial infarct size via the δ-opioid receptor in rats during reperfusion. Anesthesia and analgesia. 2009;109(5):1395.
Hosseini SK, Masoudkabir F, Vasheghani-Farahani A, Alipour-Parsa S, Fathollahi MS, Rahimi-Foroushani A, et al. Opium consumption and coronary atherosclerosis in diabetic patients: a propensity score-matched study. Planta medica. 2011;77(17):1870-5.
Hassanian-Moghaddam H, Afzali S, Pooya A. Withdrawal syndrome caused by naltrexone in opioid abusers. Human & experimental toxicology. 2014;33(6):561-7.
Sabzghabaee AM, Eizadi-Mood N, Gheshlaghi F, Javani A, Shirani S, Aghaabdollahian S. Role of Benzodiazepines in the management of agitation due to inappropriate use of Naltrexone. Iranian journal of nursing and midwifery research. 2012;17(5):365.
Schuckit MA. Treatment of Opioid-Use Disorders. New England Journal of Medicine. 2016;375(4):357-68.
Nathaniel C. Recurrent stress-induced cardiomyopathy: A case report and review article. Case reports in medicine. 2011;2011.
Reece AS, Hulse GK. Elevation of central arterial stiffness and vascular ageing in opiate withdrawal: cross-sectional and longitudinal studies. Cardiovascular toxicology. 2013;13(1):55-67.
van Dorp EL, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert opinion on drug safety. 2007;6(2):125-32.
Fuertes G, Laorden ML, Milanes MV. Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal. Neuroendocrinology. 2000;71(1):60-7.
Milanés M, Fuente T, Laorden M. Catecholaminergic activity and 3', 5'-cyclic adenosine monophosphate levels in heart right ventricle after naloxone induced withdrawal. Naunyn-Schmiedeberg's archives of pharmacology. 2000;361(1):61-6.
Laorden ML, Fuertes G, González-Cuello A, Milanés MV. Changes in catecholaminergic pathways innervating paraventricular nucleus and pituitary-adrenal axis response during morphine dependence: implication of α1-and α2-adrenoceptors. Journal of Pharmacology and Experimental Therapeutics. 2000;293(2):578-84.
Wittstein IS. Stress cardiomyopathy: a syndrome of catecholamine-mediated myocardial stunning? Cellular and molecular neurobiology. 2012;32(5):847-57.
Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. New England Journal of Medicine. 2005;352(6):539-48.
Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008;118(4):397-409.
Boyce S, Armstrong P, Stevenson J. Effect of innappropriate naltrexone use in a heroin misuser. Emergency medicine journal. 2003;20(4):381-2.
Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. 2007.
Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. The American journal on addictions. 2003;12(s2):S5-S18.
- Abstract Viewed: 275 times
- PDF Downloaded: 140 times
- HTML Downloaded: 51 times
